In 2015, Domain Therapeutics launched Kaldion, a IP holding company, to harness the potential of its adenosine programs. Kaldion granted its first license to CleveXel Pharma, who will develop a preclinical candidate for Parkinson’s disease. In 2017, Kaldion granted an exclusive license to Domain to develop A2AR antagonists in immuno-oncology in collaboration with Merck (see press release).

Program description

Adenosine A2AR antagonists (exit)

  • Discovery
  • Candidate
  • Preclinical
  • Clinical

Other Programs

NPFFR small molecule antagonist to combat the opioid crisis


PAR2 negative allosteric modulator for rare inflammatory diseases